One hundred years after the discovery of Alzheimer's disease. A turning point for therapy?

Journal of Alzheimer's Disease

Volumn 12, Issue 1, 2007, Pages 37-52

  Giacobini, Ezio ^a   Becker, Robert E ^b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b Health Pragmatics Inc   (United States)

Author keywords

Alzheimer disease; Amyloid ; Tau; Therapy

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; CLIOQUINOL; GAMMA SECRETASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMATINIB; INDOMETACIN; LEVO FLURBIPROFEN; LY 450139; MUSCARINIC M1 RECEPTOR AGONIST; NERVE GROWTH FACTOR; NEUROPEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOMER; PROTEIN KINASE C; RETINOID; ROSIGLITAZONE; SULINDAC SULFIDE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ASEPTIC MENINGOENCEPHALITIS; BACKACHE; BRAIN ATROPHY; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DNA MODIFICATION; DOSE RESPONSE; DRUG INHIBITION; DRUG WITHDRAWAL; FIBROBLAST; GASTROINTESTINAL TOXICITY; GENE THERAPY; HUMAN; IMMUNIZATION; LONG TERM CARE; MENINGOENCEPHALITIS; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SENILE PLAQUE; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34548570017     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2007-12105     Document Type: Conference Paper

References (53)

1. E. Giacobini, Cholinesterase in human brain: the effect of cholinesterase inhibitors on Alzheimer's Disease and related disorders, in: The Brain Cholinergic System in Health and Disease, E. Giacobini and G. Pepeu, eds, Informa Healthcare, 2006, pp. 235-264.
2. S. Shumaker, A. Legault and C. Kuller, Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women health initiative memory study (WHIMS), JAMA 291(24) (2004), 2947-2958.
3. D.L. Sparks, M. Sabbagh and D. Connor, Do statins slow down deterioration in AD? The ADCLT open-label extension, Neurobiol of Aging 27 (2006), S19.
4. L. Thal, Status of primary prevention trials in Alzheimer Disease, Neurobiol of Aging (2006), S21.
5. C.H. Kawas, Medications and the diet, Alz Dis Assoc Disord 20(2) (2006), S89-S96.
6. B. Zhou, S. Teramukai and M. Fukushima. Prevention and treatment of dementia or Alzheimer's Disease by statins: a meta-analysis, Dementia 23 (2007), 194-201.
7. P.L. McGeer and E.G. Mc. Geer, NSAIDS and Alzheimer disease: epidemiological, animal model and clinical studies, Neurobiology of Aging 28 (2007), 639-647.
8. A. Alzheimer, Uber eine eigenartige Erkrankung der Hirnrinde, Allg Zeitschrift Psych 64 (1907), 146-148.
9. R.D. Terry, Alzheimer's Disease at mid century (1927-1977), in: Alzheimer: 100 Years and Beyond, M. Jucker, K. Beyreuther, C. Haas and R. Nitsch, eds, Springer-Verlag, Berlin Heidelberg, 2006, pp. 58-61.
10. R.D. Terry, E. Masliah, D.P. Salmon and N. Butters, Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment, Ann Neurol 30 (1991), 572-580.
11. K. Hshiao Ashe, Commentary on Correlative deficits, Aβ elevation and amyloid plaques in transgenic mice, in: Alzheimer: 100 Years and Beyond, M. Jucker, K. Beireuther, C. Haas and R. Nitsch, eds, Springer-Verlag, Berlin Heidelberg, 2006, pp. 171-172.
12. W.E. Klunk and C.A. Mathis, Imaging the pathology of Alzheimer's disease: Building on a century-old blueprint, in: Alzheimer's Disease: 100 Years and Beyond, M. Jucker, K. Beireuther, C. Haas and R. Nitsch, Springer-Verlag, Berlin Heidelberg, 2006, pp. 399-403.
13. J. Hardy, The amyloid hypothesis : history and alternatives, in: Alzheimer's Disease: 100 Years and Beyond, M. Jucker, K. Beireuther, C. Haas and R. Nitsch, eds, Springer-Verlag, Berlin Heidelberg, 2006, pp. 151-154.
14. D. Shenk, D. Games and P. Seubert, Abeta immunotherapy prevents and reverses Alzheimer' s disease neuropathology, in: Alzheimer's Disease: 100 Years and Beyond, M. Jucker, K. Beireuther, C. Haas and R. Nitsch, eds, Springer-Verlag, Berlin Heidelberg, 2006, pp. 419-422.
15. R.B. De Mattos, Peripheral anti-Abeta antibody alters CNS and plasma Aβ clearance and decreases Aβ burden in a mouse model of Alzheimer's disease, Proc Natl Acad Sci USA 98 (2001), 8850-8855.
16. M.E. Risner, A.M. Saunders, J.F. Altman and G.C. Ormandy, Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's Disease, Pharmacogenomics J 6 (2006), 246-254.
17. P. Kermer, J. Liman, J.H. Weishaupt and M. B̈ahr, Neuronal apoptosis in neurodegenerative diseases: from basic research to clinical application, Neurodeg Dis 1 (2004), 9-19.
18. C. Soto, Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease, Mol Med Today 5 (1999), 343-350.
19. B. Solomon, Anti-aggregating antibodies, a new approach towards treatment of conformational disease, Curr Med Chem 9 (2002), 1737-1749.
20. Saido, Catabolism of amyloid beta peptide and pathogenesis of sporadic Alzheimner' s disease, in: Alzheimer's Disease: 100 Years and Beyond, M. Jucker, K. Beireuther, C. Haas and R. Nitsch, Springer-Verlag, Berlin Heidelberg, 2006, pp. 201-206.
21. J.P. Cleary, D.W. Walsh and J. Hofmeister, Natural oligomers of the amyloid-beta-protein specifically disrupt cognitive function, Nature Neurosc 8 (2005), 79-84.
22. S. Lesne, M.T. Koh and L. Kotilinek, A specific amyloid-beta-protei assembly in the brain impairs memory, Nature 440 (2006), 352-357.
23. G.M. Shankar, B.L. Bloodgood, M. Townsend, D.W. Walsh and D.J. Selkoe, Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signalling pathways, J Neurosc 27 (2007), 2866-2875.
24. W.L. Klein, Synaptic targeting by Aβ olygomers (ADDLS) as a basis for memory loss in early Alzheimer's disease, Alzheimer's and Dementia 2 (2006), 43-55.
25. H. Braak and K. Del Tredici, Staging of cortical neurofibrillary inclusions of the Alzheimer's type, in: Alzheimer's Disease: 100 Years and Beyond, M. Jucker, K. Beireuther, C. Haas and R. Nitsch, eds, Springer-Verlag, Berlin Heidelberg, 2006, pp. 97-106.
26. F. Fahrenholz, Activation of alpha-secretase as an approach for treatment of Alzheimer's disease, in: Alzheimer's Disease: 100 Years and Beyond, M. Jucker, K. Beireuther, C. Haas and R. Nitsch, eds, Springer-Verlag, Berlin Heidelberg, 2006, pp. 255-259.
27. M. Citron, Strategies for disease modification in Alzheimer's disease, Nature Rev Neurosc 5 (2004), 677-685.
28. X. Hu, C.W. Hicks and W.H. He, Bace 1 modulates myelination in the central and peripheral nervous system, Nature Neurosc 9 (2006), 1520-1525.
29. W.E. Klunk, H. Engler and A. Nordberg, Imaging the pathology of Alzheimer's disease: amyloid imagingwith positron emission tomography, in: Neurologic Application of Positron Emission Tomography, C. Meltzer, ed., W. Saunders Co. Philadelphia, 2003, pp. 781-789.
30. H. Engler, A. Forsberg and O. Almqvist, Two-year follow up of amyloid deposition in patients with Alzheimer's disease, Brain 10 (2006), 178-189.
31. D. Schenk, R. Barbour and W. Dunn, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature 400 (1999), 173-177.
32. S. Gilman, M. Koller and R.S. Black, Clinical effects of Aβ immunization (AN 1792) in patients with AD in an interrupted trial, Neurology 64 (2005), 1553-1562.
33. N.C. Fox, R.S. Black and S. Gilman, Effects of Aβ immunization on MRI measures of cerebral volume in Alzheimer' disease, Neurology 64 (2005), 1563-1572.
34. B. Solomon, Alzheimer' s disease and Immunology, Curr Alz Res 1 (2004), 149-163.
35. C. Hock, U. Konietzko and J.R. Streffer, Antibodies against beta-amyloid slow cognitive decline in Alzheimer's Disease, Neuron 38 (2003), 547-554.
36. C. Hock and R. Nitsch, Clinical observations with AN-1792 using TAPIR analyses, Neurodeg Dis 2 (2005), 273-276.
37. I. Ferrer, M. Boada Rovira and M.L. Sanchez Guerra, Neuropathology and neuropathogenesis of encephalitis following amyloid-beta immunization in Alzheimers' s disease, Brain Pathol 14 (2004), 11-20.
38. J.A. Nicoll, D. Wilkinson and C. Holmes, Neuropathology of human Alzheimer's disease after immunization: with amyloid-beta peptide: case report, Nature Med 9 (2003), 448-452.
39. R. Nitsch, Immunotherapy of Alzheimer' s disease, Neurobiol of Aging 27 (2006), S15.
40. N. Fox, Immunotherapy of AD: MR imaging of changes in brain morphology, Neurobiol of Aging 27 (2006), S8.
41. J. Nicoll, The effects of Aβ immunization on the pathology of Alzheimer's disease, Neurobiol of Aging 27 (2006), S15.
42. H. Geerts, Glucosoaminoglycan mimetics (NC-231), Curr Opin Investig Drugs 5 (2004), 95-100.
43. R.A. Cherny, C.S. Atwood and M.E. Xilinas, Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice, Neuron 30 (2001), 665-676.
44. R. Schliebs and T. Arendt, The significance of the cholinergic system in the brain during aging and in Alzheimer's disease, J Neural Transm 113 (2006), 1625-1644.
45. K. FS:Bell, A. Ducantezeiler and A. Ribeiro-da-Silva, The amyloid pathology progresses in a neurotransmitter-specific manner, Neurobiol of Aging 27 (2006), 1644-1657.
46. R. Levi-Montalcini and L. Aloe, Tropic, trophic and transforming effects of Nerve Growth Factor, in: Histochemistry and Cell Biology of Autonomic Neurons, O. Er̈ank̈o, ed., Raven Press, New York, 1980, pp. 3-15.
47. A. Seiger, A. Nordberg and H. Von Holst, Intracranial perfusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy, Beh Brain Res 57 (1993), 255-261.
48. M. Eriskdotter-Jönhagen, A. Nordberg and K. Amberla, Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease, Dement Geriatr Cogn Disord 9 (1998), 246-257.
49. M.H. Tuszynski, L. Thal and M. Pay, A phase 1 cinical trial of nerve growth factor gene therapy for Alzheimer' s disease, Nature Med 11 (2005), 551-555.
50. M.H. Tuszynski, L. Thal and M. Pay, Growth factor gene delivery for Alzheimer Disease, Neurobiology of Aging 27 (2006), S93.
51. R. De Rosa, A.A. Garcia and C. Briaschi, Intranasal administration of NGF Memory deficits in AD11 anti-NGF transgenic mice, Proc Natl Acad Sci USA 102 (2005), 3811-3816.
52. A. Lambiase, L. Pagani and V. Di Fausto, Nerve growth factor eye drop administered on the ocular surface of rodents affects the nucleus basalis and septum, Brain Res 1127(1) (2007), 45-51.
53. R.S. Doody, S. Gavrilova, M. Sano, R. Thomas, P. Aisen, L. Seely and S. Hung, Dimebon improves cognition, function and behaviour in patients with mild to moderate Alzheimer's Disease : results of a randomized clinical trial, Neurodeg Dis 4(suppl 1) (2007), 282.